| Trial ID: | L5645 |
| Source ID: | NCT00812032
|
| Associated Drug: |
Aspirin
|
| Title: |
Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients
|
| Acronym: |
DM-ASA 001
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Aspirin|DRUG: aspirin
|
| Outcome Measures: |
Primary: An exploratory study with three co-primary response variables which are directly related to platelet COX-1 inhibition: arachidonic acid-induced platelet aggregation in whole blood and PRP and in the Cone-and-Plate(let) Assay (CPA), 12 or 24 hours after last dose of Aspirin | Secondary: Indirectly COX-related platelet aggregation induced by collagen or ADP, and thromboxane metabolite excretion., 12 or 24 hours after last dose of aspirin
|
| Sponsor/Collaborators: |
Sponsor: Karolinska Institutet
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2008-01
|
| Completion Date: |
2010-10
|
| Results First Posted: |
|
| Last Update Posted: |
2022-05-27
|
| Locations: |
Department of Medicine, Clinical pharmacology Unit, Karolinska University Hospital, Solna., Stockholm, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00812032
|
